In a review of publicly reported diabetes quality measures for Medicaid fee-for-service, overall reporting was found to be low and reports of outcomes measures were rarely available. For the review, published in AJPB, researchers reviewed publicly reported diabetes quality measures for Medicaid fee-for-service (FFS) programs in all 50 states and the District of Columbia. Their objective was to provide insights into the extent of diabetes quality measure reporting (ie, which diabetes quality measures are being reported and what percentage of states are using the diabetes Healthcare Effectiveness Data and Information Set [HEDIS] measures) and into the quality of care being provided (ie, achievement of established goals in diabetes care and state-level performance on diabetes quality measures). Results from the review show the number of Medicaid FFS programs reporting these data was low: 23 states reported data on at least 1 HEDIS measure. The most common measures reported were process measures (eg, retinal eye exams and HbA1c testing); outcomes measures such as the proportion of patients achieving goal were much less frequently available. Few states had historical data available, which limits the opportunity for retrospective analyses or quality benchmarking. The research provides an understanding of the current landscape of quality measures for the Medicaid diabetes population which is critical to designing and implementing initiatives aimed at improving the quality of care for individuals living with diabetes.
- Low Reporting of Medicaid Diabetes Quality Measures: Room for Improvement? The American Journal of Pharmacy Benefits (AJPB). November 16 2017